Literature DB >> 1312945

In vitro enzyme activation with calbindin-D28k, the vitamin D-dependent 28 kDa calcium binding protein.

P D Reisner1, S Christakos, T C Vanaman.   

Abstract

Purified porcine erythrocyte membrane Ca(2+)-ATPase and 3':5'-cyclic nucleotide phosphodiesterase were stimulated in a dose-dependent, saturable manner with the vitamin D-dependent calcium binding protein from rat kidney, calbindin-D28k (CaBP-D28k). The concentration of CaBP-D28k required for half-maximal activation (K0.5 act.) of the Ca(2+)-ATPase was 28 nM compared to 2.2 nM for calmodulin (CaM), with maximal activation equivalent upon addition of either excess CaM or CaBP-D28k. 3':5'-Cyclic nucleotide phosphodiesterase (PDE) also showed equivalent maximum saturable activation by calbindin (K0.5 act. = 90 nM) or calmodulin (K0.5 act. = 1.2 nM). CaBP-D28k was shown to effectively compete with CaM-Sepharose for PDE binding. Immunoprecipitation with CaBP-D28k antiserum completely inhibited calbindin-mediated activation of PDE but had no effect on calmodulin's ability to activate PDE. While the physiological significance of these results remains to be established, they do suggest that CaBP-D28k can activate enzymes and may be a regulator of yet to be identified target enzymes in certain tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312945     DOI: 10.1016/0014-5793(92)80342-e

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Intracellular calcium ion response to glucose in beta-cells of calbindin-D28k nullmutant mice and in betaHC13 cells overexpressing calbindin-D28k.

Authors:  Jai Parkash; Muhammad A Chaudhry; Ayman S Amer; Sylvia Christakos; William B Rhoten
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

2.  Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity.

Authors:  B K Ho; M E Alexianu; L V Colom; A H Mohamed; F Serrano; S H Appel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Calbindin D28k targets myo-inositol monophosphatase in spines and dendrites of cerebellar Purkinje neurons.

Authors:  Hartmut Schmidt; Beat Schwaller; Jens Eilers
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

Review 4.  Calcium-binding proteins: selective markers of nerve cells.

Authors:  C Andressen; I Blümcke; M R Celio
Journal:  Cell Tissue Res       Date:  1993-02       Impact factor: 5.249

Review 5.  Cytosolic Ca2+ buffers.

Authors:  Beat Schwaller
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-10-13       Impact factor: 10.005

6.  The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson's disease.

Authors:  Hong-Hua Yuan; Ren-Jin Chen; Yu-Hua Zhu; Chang-Ling Peng; Xiao-Rong Zhu
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

7.  Immunocytochemical localization of the plasma membrane calcium pump, calbindin-D28k, and parvalbumin in Purkinje cells of avian and mammalian cerebellum.

Authors:  N Tolosa de Talamoni; C A Smith; R H Wasserman; C Beltramino; C S Fullmer; J T Penniston
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  Calbindin-D9k expression in the pregnant cow uterus and placenta.

Authors:  J D Reiswig; G S Frazer; N Inpanbutr
Journal:  Histochem Cell Biol       Date:  1995-08       Impact factor: 4.304

9.  Calbindin influences response to photic input in suprachiasmatic nucleus.

Authors:  Toshiyuki Hamada; Joseph LeSauter; Maria Lokshin; Maria-Teresa Romero; Lily Yan; Judith M Venuti; Rae Silver
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

Review 10.  The renaissance of Ca2+-binding proteins in the nervous system: secretagogin takes center stage.

Authors:  Alán Alpár; Johannes Attems; Jan Mulder; Tomas Hökfelt; Tibor Harkany
Journal:  Cell Signal       Date:  2011-10-01       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.